Healthcare resource utilization for anemia management: Current practice with erythropoiesis-stimulating agents and the impact of converting to once-monthly C.E.R.A.

Blood Purification

Volumn 26, Issue 6, 2008, Pages 537-546

  Saueressig, Ulrich ^a   Kwan, Jonathan T C ^b   De Cock, Erwin ^c   Sapède, Claudine ^d  

^a Gemeinschaftspraxis   (Germany)

^b ST HELIER HOSPITAL   (United Kingdom)

^c United BioSource Corporation   (Spain)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Anemia; Chronic kidney disease; Continuous erythropoietin receptor activator; Cost; Dialysis; Erythropoiesis stimulating agents; Time savings

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GERMANY; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TASK PERFORMANCE; UNITED KINGDOM;

ANEMIA; COST SAVINGS; DISEASE MANAGEMENT; ERYTHROPOIETIN; GERMANY; GREAT BRITAIN; HEALTH PERSONNEL; HEALTH RESOURCES; HEMATINICS; HUMANS; POLYETHYLENE GLYCOLS; TASK PERFORMANCE AND ANALYSIS;

EID: 55449131125     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000171873     Document Type: Article

References (30)

1. Lysaght MJ: Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002;13:S37-S40.
2. Xue JL, Ma JZ, Louis TA, Collins AJ: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001;12:2753-2758.
3. US Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006.
4. Osinski M, Wish J: Physician workforce: coming up short. Nephrol News Issues 2005;19:58-59, 64, 67.
5. Kerr PG: Renal anaemia: recent developments, innovative approaches and future directions for improved management. Nephrology 2006;11:542-548.
6. Roderick P, Nicholson T, Armitage A, Mehta R, Mullee M, Gerard K, Drey N, Feest T, Greenwood R, Lamping D, Townsend J: An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales. Health Technol Assess 2005;9:1-178.
7. Kleophas W, Reichel H: International study of health care organization and financing: development of renal replacement therapy in Germany. Int J Health Care Finance Econ 2007;7:185-200.
8. Nicholson T, Roderick P: International Study of Health Care Organization and Financing of Renal Services in England and Wales. Int J Health Care Finance Econ 2007;7:283-299.
9. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J: Association of kidney function with anaemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162:1401-1408.
10. Hsu CY: Epidemiology of anaemia associated with chronic renal insufficiency. Curr Opin Nephrol Hypertens 2002;11:337-341.
11. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, Tse TF, Wasserman B, Leiserowitz M: The prevalence of anaemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501-1510.
12. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM: The effects of higher haemoglobin levels on mortality and hospitalization in haemodialysis patients. Kidney Int 2003;63:1908-1914.
13. Li S, Collins AJ: Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 2004;65:626-633.
14. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, Mendelssohn DC, Held PJ, Port FK: Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:94-111.
15. Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, Burrows-Hudson S, Messana JM, Levin N, Rajagopalan S, Port FK, Wolfe RA, Saran R: Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 2005;45:658-666.
16. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-1191.
17. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19:ii1-ii47.
18. KDOQI: KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530.
19. Locatelli F, Conte F, Marcelli D: The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 1998;13:1642-1644.
20. Xia H, Ebben J, Ma JZ, Collins AJ: Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999;10:1309-1316.
21. Gouva C, Nikolopoulos P, Ioannidis JPA, Siamopoulos KC: Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004;66:753-760.
22. Dean BB, Dylan M, Gano A Jr, Knight K, Ofman JJ, Levine BS: Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005;21:981-987.
23. Locatelli F, Villa G, de Francisco AL, Albertazzi A, Adrogue HJ, Dougherty FC, Beyer U; BA16286 Study Investigators: Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin 2007;23:969-979.
24. Levin NW, Fishbane S, Cañedo FV, Zeig S, Nassar GM, Moran JE, Villa G, Beyer U, Oguey D; MAXIMA study investigators: Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370:1415-1421.
25. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; PROTOS Study Investigators: Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2:637-646.
26. Asadi MJ, Baltz WA: Activity-based costing for clinical paths. An example to improve clinical cost & efficiency. J Soc Health Syst 1996;5:1-7.
27. Moore T, Chookie S: Extended dosing of darbepoetin alfa in patients with chronic kidney disease not on dialysis: a review of recent data. Nephrol Nurs J 2005;32:399-407.
28. Port FK, Pisoni RL, Bragg-Gresham JL, Satayathum SS, Young EW, Wolfe RA, Held PJ: DOPPS estimates of patient life years attributable to modifiable hamodialysis practices in the United States. Blood Purif 2004;22:175-180.
29. Kotanko P, Thijssen S, Levin NW: Association between erythropoietin responsiveness and body composition in dialysis patients. Blood Purif 2008;28:82-89.
30. Ofsthun N, Lazarus JM: Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients. Blood Purif 2007;35:31-35.